Document is current

Article History

Received: 1 March 2024

Accepted: 25 July 2024

First Online: 2 August 2024

Declarations

:

: The protocol and other relevant documents were approved by an Institutional Review Board before the study was initiated. The study was conducted in accordance with the protocol and ethical principles derived from international guidelines including the Declaration of Helsinki, and the International Conference on Harmonization Good Clinical Practice Guidelines, as well as any applicable laws, rules, and regulations. Participants or their legally authorized representative provided written informed consent.

: Not applicable.

: MN, YH, and MT are employees of Sanofi and may hold shares and/or stock options in the company. ST was an employee of Sanofi at the time of this study. KI reports honoraria from Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb K.K., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K, Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Meiji Seika Pharma Co. Ltd., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Towa Pharmaceutical Co., Ltd., AstraZeneca K.K., Nippon Kayaku Co., Ltd., Alexion Pharmaceuticals, Inc., AbbVie GK., Sanofi K.K., and Amgen K.K. YM reports consultancy from Zenyaku Kogyo, Argenx, Sanofi, and Pfizer; and research funding from Argenx, Sanofi, and Pfizer. SI and HU have no disclosures. YU reports honoraria from Sanofi, AbbVie, and Novo Nordisk; and speakers bureau from Sanofi. MM reports consultancy from Takeda, Sanofi, Alexion Pharma; research funding from Sanofi, Alexion Pharma, Chugai Pharmaceutical, and Asahikasei Pharma; and speakers bureau from Sanofi, Takeda, Alexion Pharma, and Asahikasei Pharma.